key: cord-0941644-r48dtscg
authors: Viswanatha, G. L.; Anjana Male, C. K. V. L. S. N.; Shylaja, H.
title: A systematic review and meta-analysis on the safety and efficacy of tocilizumab in the management of COVID-19
date: 2021-01-29
journal: nan
DOI: 10.1101/2021.01.27.21250599
sha: 240698291bd28e03a8cc39f0f08caeb24a80e1da
doc_id: 941644
cord_uid: r48dtscg

Background: This systematic review and meta-analysis was aimed to evaluate the therapeutic benefits and safety of tocilizumab (TCZ) in treating severe coronavirus disease 2019 (COVID-19) and associated health complications. Methods: The electronic search was performed using PubMed, Scopus, CENTRAL (Cochrane Central Register of Controlled Trials (RCTs) and Google scholar databases to identify the randomized control trials. Mortality, incidences of ICU admission, need of mechanical ventilation (MV), length of stay in the hospital (LOS) and length of stay in the ICU (LOS-ICU) and the incidences of super-infection, bacteraemia, fugleman, pneumonia and pulmonary thrombosis were evaluated as the primary outcomes. The comparison will be between TCZ versus standard of care (SOC)/placebo. Results: Based on the inclusion criteria there were 24 retrospective studies involving 5686 subjects were included. The outcomes of the meta-analysis have revealed that the TCZ has reduced the mortality (Mantel-Haenszel (M-H), random effects risk difference (RE-RD) of -0.11 (-0.18 to -0.04), at 95% CI, p = 0.001, I2 = 88%) and increased the incidences of super-infections (M-H, RE-Risk ratio (RR) of 1.49 (1.13 to 1.96) at 95% CI, p=0.004, I2 = 47%). However, there is no significant difference in ICU admissions rate (M-H, RE-RD of -0.06 (-0.23 to 0.12) at 95% CI, p=0.54, I2 = 93%), need of MV (M-H, RE-RD of 0.00 (-0.06 to 0.07) at 95% CI, p=0.96, I2 = 74%), LOS (Inverse variance (IV): -2.86 (-0.91 to 3.38) at 95% CI, p=0.37, I2 = 100%), LOS-ICU (IV: -3.93 (-12.35 to 4.48) at 95% CI, p=0.36, I2 = 100%), and incidences of pulmonary thrombosis (M-H, fixed effect odds ratio (FE-OR) of 1.01 (0.45 to 2.26) at 95% CI, p=0.99, I2 = 0%) compared to SOC/control. Conclusion: This meta-analysis was performed using retrospective clinical reports on use of tocilizumab in COVID-19, and based on the outcomes of the meta-analysis we can conclude that administration of TCZ would reduce the risk of mortality, and however there is no much difference observed between the TCZ and SOC/control groups in other parameters such as ICU admission rate, need of mechanical ventilation and Length of hospital stay (ICU and Non-ICU). On the other hand, TCZ treated subjects possess higher chances of super-infections and pneumonia compared with SOC/control group. However, there is a need for multi-centric randomized trials to determine the potential therapeutic role of TCZ in mitigating COVID-19 and associated health complications.

Corona virus diseases (COVID-19) is a viral disease caused by severe acute respiratory 12 syndrome corona virus-2(SARS-CoV-2) that originated from Wuhan city of Hubei province 13 in China in December 2019 [1] . Globally it has caused significant burden on public health 14 through drastic increase in the morbidity and mortality rate [2] . The available evidence 15 suggests that most of the infected patients will remain asymptomatic or develop mild 16 symptoms, however nearly 20% of the infected individuals would develop severe pneumonia the blood is highly correlated with the mortality rate in the COVID-19 infected patients 1 [12] .The activation of IL-6 amplifier would induce cytokine storm, an hallmark of 2 dysregulated inflammation, and thus inhibition or blockade of IL-6 amplifier would alleviated 3 cytokine storm in COVID-19 [12] .In these lines many studies have reported that TCZ 4 administration could stabilize the health status of COVID-19 patients by improving 5 respiratory functions, reducing CRP levels and improved health deteriorations due to 6 COVID-19 [12] . In addition, there are multiple case study series, retrospective and 7 prospective study reports available on the therapeutic benefits of TCZ in COVID-19. 8 However, there is no randomized controlled studies completed or available related to use of 9 TCZ in COVID-19. In this context, there are several randomized controlled trials registered 10 and under progress to evaluate the clinical benefits of TCZ in alleviating COVID-19 and 11 associated health problems (phase II; NCT04317092, NCT04445272, NCT04377659, phase 12 III; NCT04320615, NCT04330638, NCT04345445) [13] . 13 With this background the present study was undertaken to evaluate the clinical benefits of 4. In-vitro and pre-clinical studies 10 5. Studies reporting qualitative outcomes without numerical data 11 2.3. Parameters 12 The parameters related to COVID-19 such as Mortality, ICU (intensive care unit) ward 13 admission rate, need of mechanical ventilation, length of hospital stay (LOS), length of 14 hospital stay in the ICU (LOS-ICU), and the incidences events such as super-infections, 15 fungemia, bacteremia, pneumonia, and pulmonary thrombosis were evaluated as the primary 16 outcomes. The comparison will be between TCZ and standard care/placebo/control. 1 Copenhagen, Denmark; 2014) shall be used to analyze the data. For continuous, variables, 2 inverse variance (IV) was estimated using the random-effects model with a standardized 3 mean difference as effect measure and for the dichotomous variables, the Mantel-Haenszel 4 (M-H) statistic was estimated using a random-effects model fixed-effects model with an odds 5 ratio (OR) as the effect measure. A random-effects model shall be used to calculate the 6 pooled prevalence with a 95% confidence interval (CI). Heterogeneity shall be calculated 7 with the I 2 statistic. This test estimates the percentage of variation between study results that 8 is due to heterogeneity rather than sampling error. I 2 of less than 40% is considered 9 unimportant while that of more than 40% is viewed as moderate to considerable 10 heterogeneity. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 29, 2021. ; https://doi.org/10.1101/2021.01.27.21250599 doi: medRxiv preprint fungemia, bacteremia, pneumonia, and pulmonary thrombosis were compared between TCZ 1 treatment versus control/SOC groups in COVID-19 positive patients. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 29, 2021. ; https://doi.org/10.1101/2021.01.27.21250599 doi: medRxiv preprint

The meta-analysis revealed that the chances of super-infections is slightly high in the TCZ 1 treated group compared to control/SOC (M-H, RE-RR of 1.59 (1.05, 2.41) at 95% CI, 2 p=0.03, I 2 = 63%), however there is a significant heterogenicity among the studies included 3 for the analysis. In the summary the incidence of super-infections, fungemia, bacteremia and pneumonia were 23 compared and analyzed between the TCZ and control/SOC groups by including a total of 24 3,686 patients out of which 2,103 (57.1%) were in the control/SOC group (never received 25 All rights reserved. No reuse allowed without permission. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in that the need for MV is same between TCZ and control/SOC treated groups. 9 Besides, length of stay (LOS and LOS-ICU) is the one of important parameter considered for 10 evaluating the efficacy in COVID-19 patients. As per the available data the median LOS was 11 found to be 4 to 21 days (outside China) and median LOS-ICU was found to be 4 to 19 days 12 (outside China) [32] . In this regard, 8 studies reporting LOS and 3 studies reporting LOS-ICU 13 were included in the present study. On the overview, the TCZ treatment has shown benefit in 14 minimizing the LOS and LOZ-ICU compared to control/SOC. However, there was no 15 statistically significant difference observed between the TCZ and control/SOC groups, due to Altogether, the meta-analysis performed based on the available literature on TCZ related to 1 its efficacy and safety in COVID-19 patients, we can conclude that the administration of TCZ 2 would reduce the risk of mortality, and however there is no much difference observed 3 between the TCZ and SOC/control groups in other parameters such as ICU admission rate, perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in The copyright holder for this this version posted January 29, 2021. ; https://doi.org/10.1101/2021.01.27.21250599 doi: medRxiv preprint randomized multi-centric clinical trials to scientifically validate the therapeutic benefit of 1 TCZ in mitigating the COVID-19 and associated health problems. perpetuity. preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in 

Pneumonia 7 of unknown aetiology in Wuhan, China: potential for international spread via 8 commercial air travel

Coronavirus disease 2019 (COVID-19): Situation Report-10

Preliminary estimation of the 12 basic reproduction number of novel coronavirus (2019-nCoV) in China, from 2019 to 13 2020: A datadriven analysis in the early phase of the outbreak

Potential Therapeutic Options for COVID-19: Current Status

COVID-19 length of hospital stay: a 11 systematic review and data synthesis

Efficacy and safety of tocilizumab in 14 severe COVID-19 patients: a single-centre retrospective cohort study